We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie Q2 Preview: Can Shares Retain Their Strength?
Read MoreHide Full Article
The Zacks Large Cap Pharmaceuticals Industry has been hot year-to-date, increasing more than 10% in value and crushing the S&P 500’s decline of approximately 15%. Buyers have defended stocks in this industry at a high level all throughout the year.
A titan in the space, AbbVie (ABBV - Free Report) , is on deck to report quarterly results before the opening bell this Friday, July 29th. AbbVie is a global research-based biopharmaceutical company that delivers innovative medicines.
In addition, the company carries a Zacks Rank #3 (Hold) with an overall VGM Score of an A. How does the company stand heading into the quarterly release? Let’s find out.
Share Performance & Valuation
There has been a surplus of buyers for AbbVie shares in 2022, with shares gaining a double-digit 15% and outperforming its Zacks Industry by a fair margin.
Image Source: Zacks Investment Research
Extending the timeframe to cover the last year, we can see that AbbVie shares enjoyed a major run all throughout the late months of 2021, with shares up a double-digit 33% in this timeframe.
Image Source: Zacks Investment Research
In addition to stellar share performance, the company also sports rock-solid valuation levels, further bolstered by its Style Score of a B for Value. AbbVie’s forward earnings multiple resides at 10.8X, representing a deep 29% premium relative to its Zacks Industry.
Image Source: Zacks Investment Research
Quarterly Estimates
Analysts have been bearish for the upcoming quarterly release – six negative estimate revisions have hit the tape over the last 60 days. However, the Zacks Consensus EPS Estimate resides at $3.31, good enough for a solid 6.4% uptick in quarterly earnings year-over-year.
Image Source: Zacks Investment Research
AbbVie’s top-line is projected to expand by a fair amount as well; the $14.7 billion quarterly revenue estimate notches a nice 5% increase compared to year-ago quarterly sales of $13.9 billion. The chart below illustrates the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
Quarterly Performance & Market Reactions
Undoubtedly a major positive, AbbVie has consistently reported bottom-line results above expectations, exceeding the Zacks Consensus EPS Estimate in nine of its previous ten quarterly reports.
Top-line results have also been rock-solid; ABBV has recorded seven top-line beats over its last ten quarters.
Buyers come out to play following AbbVie’s quarterly results, with shares moving upwards four times out of its previous six earnings releases.
Bottom Line
Share performance has been stellar, and the company is forecasted to register single-digit top and bottom-line growth. However, analysts have been bearish over the last 60 days, a reflection of the harsh macroeconomic backdrop we’re currently in.
In addition, the company has consistently exceeded earnings estimates, and the market has reacted well as of late following quarterly reports.
Heading into the release, AbbVie (ABBV - Free Report) carries a Zack Rank #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
AbbVie Q2 Preview: Can Shares Retain Their Strength?
The Zacks Large Cap Pharmaceuticals Industry has been hot year-to-date, increasing more than 10% in value and crushing the S&P 500’s decline of approximately 15%. Buyers have defended stocks in this industry at a high level all throughout the year.
A titan in the space, AbbVie (ABBV - Free Report) , is on deck to report quarterly results before the opening bell this Friday, July 29th. AbbVie is a global research-based biopharmaceutical company that delivers innovative medicines.
In addition, the company carries a Zacks Rank #3 (Hold) with an overall VGM Score of an A. How does the company stand heading into the quarterly release? Let’s find out.
Share Performance & Valuation
There has been a surplus of buyers for AbbVie shares in 2022, with shares gaining a double-digit 15% and outperforming its Zacks Industry by a fair margin.
Image Source: Zacks Investment Research
Extending the timeframe to cover the last year, we can see that AbbVie shares enjoyed a major run all throughout the late months of 2021, with shares up a double-digit 33% in this timeframe.
Image Source: Zacks Investment Research
In addition to stellar share performance, the company also sports rock-solid valuation levels, further bolstered by its Style Score of a B for Value. AbbVie’s forward earnings multiple resides at 10.8X, representing a deep 29% premium relative to its Zacks Industry.
Image Source: Zacks Investment Research
Quarterly Estimates
Analysts have been bearish for the upcoming quarterly release – six negative estimate revisions have hit the tape over the last 60 days. However, the Zacks Consensus EPS Estimate resides at $3.31, good enough for a solid 6.4% uptick in quarterly earnings year-over-year.
Image Source: Zacks Investment Research
AbbVie’s top-line is projected to expand by a fair amount as well; the $14.7 billion quarterly revenue estimate notches a nice 5% increase compared to year-ago quarterly sales of $13.9 billion. The chart below illustrates the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
Quarterly Performance & Market Reactions
Undoubtedly a major positive, AbbVie has consistently reported bottom-line results above expectations, exceeding the Zacks Consensus EPS Estimate in nine of its previous ten quarterly reports.
Top-line results have also been rock-solid; ABBV has recorded seven top-line beats over its last ten quarters.
Buyers come out to play following AbbVie’s quarterly results, with shares moving upwards four times out of its previous six earnings releases.
Bottom Line
Share performance has been stellar, and the company is forecasted to register single-digit top and bottom-line growth. However, analysts have been bearish over the last 60 days, a reflection of the harsh macroeconomic backdrop we’re currently in.
In addition, the company has consistently exceeded earnings estimates, and the market has reacted well as of late following quarterly reports.
Heading into the release, AbbVie (ABBV - Free Report) carries a Zack Rank #3 (Hold).